Curis buys 51% of Uninova as UAE pharmacies watch generic supply costs

Curis Lifesciences Limited has made its 51% stake in Uninova Lifesciences Pvt. Ltd. the centre of a three-part growth plan covering branded generics, Kenya exports and a Nigeria manufacturing route.

For UAE pharmacy operators, the immediate issue is market access, not the acquisition itself. Any Curis or Uninova product sold in Dubai pharmacies needs federal medicine registration through the Ministry of Health and Prevention (MOHAP), then distribution through licensed drug stores and pharmacies regulated locally by Dubai Health Authority (DHA), Department of Health Abu Dhabi (DOH) or MOHAP in the northern emirates.

What Curis is changing

The BusinessWire India release carried by Business Standard said Curis wants to use Uninova to build its domestic branded pharmaceutical business while strengthening merchant exports in Kenya and establishing a longer-term pharmaceutical presence in Nigeria. The earlier transaction notice said Curis paid ₹20,65,500 for 1,53,000 shares, equal to 51% of Uninova, and that Uninova reported ₹5.39 crore of topline in FY2024-25.

We are focused on building a diversified pharmaceutical platform with multiple growth engines across domestic branded pharmaceuticals, contract manufacturing and international markets.
Mr. Dharmesh Patel, Chairman and Managing Director, Curis Lifesciences Limited

Curis is still small by UAE procurement standards. Its ₹27.52 crore SME IPO in November 2025 was positioned around plant upgrades, storage capacity, product registrations abroad, loan repayment and working capital. IPO coverage at the time said contract and loan-license manufacturing contributed more than 98% of FY25 revenue, while own-brand exports were less than 1% and focused on markets such as Yemen and Kenya.

Why UAE operators should care

Dubai comes first because private outpatient prescribing and retail pharmacy volume make it the fastest place to test demand. A new Indian branded-generic supplier can affect pharmacy margins if it enters high-volume chronic categories, but UAE sale requires MOHAP registration, approved pricing and compliant Arabic-English labelling. MOHAP’s own registration guidance lists AED 7,000 for registering a conventional or biological medicine product and AED 3,500 for product analysis or re-analysis.

• CFOs should ask whether any Curis or Uninova item has a UAE registration number, approved public price and distributor margin before modelling savings.
• COOs should check that the dispensing site is licensed by DHA in Dubai, DOH in Abu Dhabi or MOHAP in the northern emirates.
• Medical directors should treat substitution as a formulary decision, tied to active ingredient, dosage form, bioequivalence evidence and patient consent rules.
• Insurers such as Daman, the Daman-administered Thiqa programme and Sukoon should watch whether a lower-priced registered alternative can be placed into network formularies without creating denial friction.

The patient impact is narrower. More suppliers can reduce out-of-pocket costs when a medicine is outside plan coverage or subject to co-pay. In Dubai, many outpatient pharmacy benefits still depend on the employer plan, annual limit, network tier and prior authorisation rule. Operators should verify the reimbursed price against the insurer schedule, not the manufacturer announcement.

What to check before buying or listing

A UAE buyer should start with three public checks. Search MOHAP’s registered medical product directory for the product name, active ingredient and registration status. Search DHA’s Dubai Medical Registry for the Dubai pharmacy or facility licence. For Abu Dhabi and Al Ain, use DOH facility channels and circulars, because pharmacy dispensing and controlled medicine handling sit under DOH oversight.

Curis has not announced a UAE launch date in the cited release. That matters. A Kenya or Nigeria route does not create automatic UAE eligibility, and an Indian branded portfolio cannot be stocked legally in Dubai or Sharjah until the UAE registration, import and distribution steps are complete.

The practical watch item is product registration, not branding. If Curis files UAE dossiers in 2026 or 2027, clinics and pharmacies should compare approved prices against current formulary alternatives before switching procurement. Until then, use the UAE Open Healthcare Directory to find licensed pharmacy providers and confirm which pharmacies can dispense under the patient’s emirate and insurance network.